UCLA scientists discover why patients respond to a life-saving melanoma drug
UCLA researchers have pioneered a new methodology to predict why some patients battling advanced melanoma respond well or not at all to the new breakthrough drug pembrolizumab (Keytruda). The study is the first of its kind since the FDA approved its use under the name Keytruda in September 2014. November 26, 2014